(Q40262211)

19 September 2017

title

Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma (English)

1 reference

19 September 2017

Xiaotian Zhang

1

1 reference

19 September 2017

Masakazu Yashiro

2

1 reference

19 September 2017

Masaichi Ohira

3

1 reference

19 September 2017

Jun Ren

4

1 reference

19 September 2017

Kosei Hirakawa

5

1 reference

19 September 2017

language of work or name

1 reference

29 June 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

97

1 reference

19 September 2017

issue

9

1 reference

19 September 2017

page(s)

938-944

1 reference

Cancer epigenetics comes of age

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Reduced expression of the TSP1 gene and its association with promoter hypermethylation in gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

DNA methylation, methyltransferases, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

The hematopathological basis for studying effects of the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Re-expression of endogenous p16ink4a in oral squamous cell carcinoma lines by 5-aza-2'-deoxycytidine treatment induces a senescence-like state

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

The DAP kinase family of pro-apoptotic proteins: novel players in the apoptotic game.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Role of the Ras-association domain family 1 tumor suppressor gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

The absence of p53 is critical for the induction of apoptosis by 5-aza-2'-deoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00253.X

10.1111/J.1349-7006.2006.00253.X

21 January 2018

Identifiers

DOI

1 reference

19 September 2017

1 reference